cannabis - Page 1 | CARLAT PUBLISHING

Research Update

Cannabis Use Frequency and Cannabis Use Disorder

June 20, 2025

Aniruddha Deka, MD. Dr. Deka has no financial relationships with companies related to this material.

Prevalence and frequency of cannabis use have increased as restrictions have been eased across the country. Here, researchers asked the question: Does frequency of cannabis use affect the likelihood of developing cannabis use disorder? The answer may surprise you.

4 Rationalizations for Cannabis Use—And How to Respond

May 26, 2025

Daniel Carlat, MD

Expert Q&A

ADHD, Stimulants, and Substance Use

April 1, 2025

Sara Polley, MD

Sara Polley, MD, Chief Medical Officer, Ellie Mental Health.

Dr. Polley has no financial relationships with companies related to this material.

Dr. Polley clarifies when to use stimulants in patients with ADHD and substance use disorders and how to address the underlying addiction.

Expert Q&A

Navigating Cannabis Withdrawal

January 1, 2025

Alan J. Budney, PhD

Alan J. Budney, PhD

Professor of Psychiatry; Professor of Biomedical Data Science; Geisel School of Medicine at Dartmouth, Lebanon, NH.

Dr. Budney has served as a scientific advisor for Jazz Pharmaceuticals and Indivior Inc. Relevant financial relationships listed for the author have been mitigated.

Cannabis withdrawal is a largely underappreciated phenomenon that nonetheless interferes with many patients’ ability to stop using cannabis. Dr. Budney discusses some of the symptomatology of cannabis withdrawal and reviews how to discuss it with our patients.

CARLAT WEBINAR

Carlat Psychiatry News - Episode 3 - Lumateperone

August 1, 2024

Chris Aiken, MD, Greg Malzberg, MD, and Kellie Newsome, PMHNP

0.25 CME Credits. Highlights from this month include Lumateperone, Lavender, treatment resistant smoking, and Clonidine patches and Tourettes. A new meta analysis published in Psychiatry Research sheds light on a critical question.

Research Update

Does Cannabis Legalization Increase the Risk of Driving-Related Injury?

July 1, 2024

Garrett Rossi, MD.

Garrett Rossi, MD. Dr. Rossi has no financial relationships with companies related to this material.

Everyone knows that it is dangerous to drive while under the influence of alcohol—but what about cannabis? This study adds to a growing body of evidence that cannabis can be hazardous to safety on the road, a particularly important message to get out to patients as legalization becomes increasingly common.

CARLAT WEBINAR

Carlat Psychiatry News - Episode 2 - TMS for Teens

June 1, 2024

Chris Aiken, MD, Greg Malzberg, MD, and Kellie Newsome, PMHNP

0.25 CME Credits. Psychiatric news covered in this episode: TMS for Teens, Olanzapine Serum Levels, Old Medication Pairing Emerges for Novel Alcoholism Treatment, Old Medication Pairing Emerges for Novel Alcoholism Treatment, Promising Option For Transitioning Insomnia Medications, Lithium's Anti-Suicide Effects in Question, Role of Omega-3 Supplements in Psychosis Risk Reduction, Caffeine and Anxiety: A Concerning Connection for Coffee Lovers.

CARLAT WEBINAR

Carlat Psychiatry News - Episode 1 - MDMA-Assisted Therapy for PTSD

April 1, 2024

Chris Aiken, MD, Greg Malzberg, MD, and Kellie Newsome, PMHNP

0.25 CME Credits. Psychiatric news covered in this episode: FDA Grants Priority Review for MDMA Therapy, Benzodiazepine Withdrawal Perils, Lithium: Good for Bones?, Iloperidone Added to Anti-Psychotics with Mania Efficacy, Transdiagnostic Sleep and Circadian Treatment, A Door Closes for Clozapine-Resistant Schizophrenia, Therapy for Multi-Trauma PTSD.

shutterstock_2423345401_Ekkasit A Siam.png

CARLAT WEBINAR

Motivational Interviewing for Teens: Focus on Marijuana

February 15, 2024

Joshua Feder, MD

0.50 CME Credits. Key strategies to empower you in reducing marijuana use among you. Join us as we delve into practical approaches to support teens in making healthier choices and navigating the stages of change.

Expert Q&A

Substance-Induced Psychosis: Diagnostic Dilemmas and Treatment Options

January 31, 2024

Nicholas Athanasiou, MD, MBA, DFASAM

Nicholas Athanasiou, MD, MBA, DFASAM.

Associate clinical professor, Psychiatry and Biobehavioral Sciences (DGSOM), UCLA Olive View Psychiatry Residency Program; Supervising Mental Health Psychiatrist, Los Angeles County Department of Mental Health, Los Angeles, CA.

Dr. Athanasiou has no financial relationships with companies related to this material.

Substance-induced psychosis (SIP) presents diagnostic challenges in distinguishing it from primary psychotic disorders, with substance timing, symptom type, and duration being key differentiators. Effective treatment combines antipsychotic medications and substance cessation strategies. Dr. Athanasiou reviews key points in the management of SIP.